Values First Advisors
PCVX icon

Values First Advisors’s Vaxcyte PCVX Stock Holding History

Values First Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$380K Sell
6,687
-81
-1% -$4.72K 0.18% 128
2026
Q2 		$393K Buy
6,768
+151
+2% +$8.2K 0.18% 131
2026
Q1 		$385K Buy
6,617
+1,937
+41% +$105K 0.2% 118
2025
Q4 		$216K Buy
+4,680
New +$209K 0.11% 161
2024
Q4 		– Sell
-1,527
Closed -$174K – 270
2024
Q3 		$174K Buy
+1,527
New +$138K 0.09% 155

Other funds holding PCVX

Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
BG Investment Services
BG Investment Services Hagatna, Guam $673M AUM 14.41% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
Avior Wealth Management
Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Teza Capital Management
Teza Capital Management Chicago, Illinois $112M AUM 57.58% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Values First Advisors's PCVX Position: Q3 2026 in Review

Values First Advisors reduced its Vaxcyte (PCVX) stake by 1.2% in Q3 2026, selling an estimated $4.72K and leaving 6,687 shares worth $380K. The position accounts for 0.18% of the portfolio, ranked #128.

Values First Advisors first reported a position in PCVX in Q3 2024 and has held it in 5 quarters since. The position peaked at $393K in Q2 2026. 59 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Values First Advisors held 6,687 shares of Vaxcyte worth $380K as of Q3 2026.
  • Values First Advisors sold 81 Vaxcyte shares in Q3 2026, an estimated $4.72K.
  • Vaxcyte made up 0.18% of Values First Advisors's portfolio in Q3 2026, its #128 holding.
  • Values First Advisors first reported a position in Vaxcyte in Q3 2024 and has held it in 5 quarters since.
  • Values First Advisors's Vaxcyte position peaked at $393K in Q2 2026.
  • 59 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Values First Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.